Invention Grant
- Patent Title: Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
-
Application No.: US16535931Application Date: 2019-08-08
-
Publication No.: US10981898B2Publication Date: 2021-04-20
- Inventor: Gianni Chessari , Steven Howard , Ildiko Maria Buck , Benjamin David Cons , Christopher Norbert Johnson , Rhian Sara Holvey , David Charles Rees , Jeffrey David St. Denis , Emiliano Tamanini , Bernard Thomas Golding , Ian Robert Hardcastle , Celine Florence Cano , Duncan Charles Miller , Martin Edward Mäntylä Noble , Roger John Griffin , James Daniel Osborne , Joanne Peach , Arwel Lewis , Kim Louise Hirst , Benjamin Paul Whittaker , David Wyn Watson , Dale Robert Mitchell
- Applicant: ASTEX THERAPEUTICS LIMITED , CANCER RESEARCH TECHNOLOGY LIMITED
- Applicant Address: GB Cambridge; GB London
- Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee Address: GB Cambridge; GB London
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: GB1517217 20150929
- Main IPC: C07D405/14
- IPC: C07D405/14 ; C07D403/06 ; C07D405/12 ; C07D413/12 ; C07D209/48 ; C07D413/06 ; C07D403/12 ; C07F9/572 ; A61P35/00
Abstract:
The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
Public/Granted literature
- US20200247789A2 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY Public/Granted day:2020-08-06
Information query
